Archigenes Pharma Sp. z o.o. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing

Secondary Activities: Merchant Wholesalers, Durable Goods | Retail Trade | Scientific Research and Development Services | Advertising, Public Relations, and Related Services | Marketing Research and Public Opinion Polling | All Other Professional, Scientific, and Technical Services | Management of Companies and Enterprises | All Other Miscellaneous Schools and Instruction | Other Personal and Household Goods Repair and Maintenance

Full name: Archigenes Pharma Sp. z o.o.

Profile Updated: May 27, 2024

Archigenes Pharma Sp. z o.o. is based in Poland, with the head office in Jozefoslaw. The company operates in the Pharmaceutical Preparation Manufacturing industry. Archigenes Pharma Sp. z o.o. was incorporated on January 31, 2019. In 2025, the company reported a net sales revenue drop of 53.23%. Its’ total assets recorded a negative growth of 26.85%. In 2025, Archigenes Pharma Sp. z o.o.’s net profit margin decreased by 63.31%.

Headquarters
Ul. Nad Strumykiem 21
Jozefoslaw; Mazowieckie; Postal Code: 05-500

Contact Details: Purchase the Archigenes Pharma Sp. z o.o. report to view the information.

Basic Information

Registered Capital:

Purchase the Archigenes Pharma Sp. z o.o. report to view the information.

Financial Auditors:

Purchase the Archigenes Pharma Sp. z o.o. report to view the information.

Incorporation Date:

January 31, 2019

Key Executives

Purchase this report to view the information.

President

Ownership Details

Purchase this report to view the information.

99%

Company Performance

Financial values in the chart are available after Archigenes Pharma Sp. z o.o. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Net sales revenue

-53.23%▼

Total Operating Revenue

-53.23%▼

Operating Profit

28.38%▲

EBITDA

18.4%▲

Net Profit/Loss for the Period

28.38%▲

Total Assets

-26.85%▼

Total Equity

-433.84%▼

Operating Profit Margin

-63.31%▼

Net Profit Margin

-63.31%▼

Return on Equity (ROE)

-524.49%▼

Similar companies